Skip to content
Search

Latest Stories

Submit Guest Post

Government moves to end cancer postcode lottery

The plan will also introduce new national standards for cancer care and expand the use of cancer detection technology and artificial intelligence to support earlier diagnosis.

cancer specialists

The government will work with the Royal Colleges to encourage more doctors to train in clinical and medical oncology.

Representational image: iStock

THE GOVERNMENT will increase the number of cancer specialists in rural and coastal areas as part of plans to end the postcode lottery in cancer care across England.

New training places will be targeted at NHS trusts with the biggest workforce gaps, with a focus on areas where patients currently face longer waits to see cancer specialists. The measures will be set out in the forthcoming National Cancer Plan.


The government will work with the Royal Colleges to encourage more doctors to train in clinical and medical oncology. The plan will also introduce new national standards for cancer care and expand the use of cancer detection technology and artificial intelligence to support earlier diagnosis.

Health and Social Care Secretary Wes Streeting said: “For too long, your chances of seeing a doctor and catching cancer early have depended on where you live. That’s not fair and has to stop.”

He added: “We’re training more doctors in the communities that need them most and making sure the latest cancer detection technology reaches every corner of the country.”

Professor Peter Johnson, National Clinical Director for Cancer at NHS England, said: “We are tackling the differences in cancer care between different parts of the country head-on with the new National Cancer Plan, so that no one needing a diagnosis or treatment is left behind.”

From April 2027, new cancer tests, devices and digital tools will go through the same approval process as medicines. Once approved, the NHS will be required to fund them.

The first technologies to be assessed include a sponge test for oesophageal cancer, software to analyse tissue samples for prostate and breast cancer, artificial intelligence to read chest X-rays for suspected lung cancer, and techniques to support faster diagnosis of endometrial cancer.

Professor Jonathan Benger, Chief Executive of NICE, said: “These reforms mean that clinically and cost-effective medical devices, diagnostics and digital tools will start to be reimbursed and made available consistently across the NHS.”

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

cancer treatment

The NHS availability announced in September 2026 applies to eligible patients in England. The treatment has already been available in Scotland for more than two years.

What is Enhertu and how could the new NHS breast cancer treatment help patients?

Highlights:
  • Enhertu is a targeted treatment for certain HER2-low breast cancers.
  • It is available for around 1,000 women in England.
  • The drug can extend survival compared with chemotherapy.
  • NICE initially rejected widespread NHS use in 2024.
  • The decision was reversed after a commercial agreement was reached.

Breast cancer treatment continues to evolve as researchers develop therapies aimed at specific characteristics of cancer cells. One such treatment is Enhertu, which has now become available on the NHS in England for people with a particular type of advanced breast cancer.

The treatment is intended for patients with HER2-low breast cancer that cannot be removed through surgery or has spread to other parts of the body. This is known as metastatic breast cancer. According to the latest announcement, around 1,000 women in England will be eligible for the treatment.

Keep ReadingShow less